H.I.G. Capital and Barts Health Launch 170,000 SF Life Science Development in London
H.I.G. Capital has announced a strategic partnership with Barts Health NHS Trust to develop a 170,000-square-foot life sciences facility at Cavell Street in London's Whitechapel district. The development will serve as the first building in the newly launched Barts Life Sciences Cluster, creating a hub for NHS-industry collaboration in MedTech, AI, and digital health.
The partnership brings together one of the UK's largest NHS Trusts and a global investment platform with $74 billion of capital under management to pioneer new models of collaboration between clinicians, researchers, and industry.
Development Details
The Cavell Street development will establish a new hub for NHS industry collaboration, enabling companies to work directly with Barts Health clinicians and researchers to shape, test, and refine next-generation technologies. The facility aims to create a state-of-the-art environment for applied healthcare innovation where MedTech and life sciences organizations can co-develop, demonstrate, and validate technologies in real clinical settings in partnership with staff from The Royal London Hospital and other Barts Health hospitals.
The development aims to create a high-performance, innovation-ready ecosystem that speeds the journey from prototype to patient and enhances the UK's capacity for NHS-embedded innovation.
Strategic Partnership for Healthcare Innovation
"Through the Barts Life Sciences Cluster, we are bringing clinicians, patients, industry, and academia together in new ways," said Shane DeGaris, Group CEO of Barts Health NHS Trust. "This first partnership project at Cavell Street begins to turn that ambition into reality. By creating environments where innovation can be shaped directly by NHS teams and tested in real care settings, we aim to improve patient outcomes and support economic opportunity for East London."
Jérôme Fouillé, Managing Director at H.I.G. Realty in Europe, commented: "We are delighted to partner with Barts Health on the Cluster's first innovation-led development. Cavell Street will create a new platform for global companies to collaborate directly with NHS clinicians, reinforcing the Cluster's position as a leading centre for applied healthcare innovation."
Barts Life Sciences Cluster
The development will serve as a landmark project within the Cluster, marking the start of a new era for health innovation in East London, defined by the integration of clinical excellence and commercial capability. The Barts Life Sciences Cluster is supported by existing and new facilities of Queen Mary University of London.
The project's focus on enabling companies to work directly with Barts Health clinicians and researchers addresses access to real-world clinical feedback for technology validation. The facility will allow MedTech and life sciences organizations to test technologies across MedTech, AI, digital health, and other emerging fields in partnership with NHS clinical settings.